Seeking Alpha

Allergan play gooses Revance

  • Traders apparently believe the potential acquisition of Allergan by Valeant and Pershing Square bodes well for Revance Therapeutics (RVNC). Shares are up 20% premarket on mediocre volume.
  • After yesterday's close, the company announced positive results from it Phase 1/2 clinical trial for RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. Its patented TransMTS technology is designed to provide a longer duration of effect.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: